Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Argos passes on IPO and raises $25m Series D to fund personalized cancer immunotherapy

This article was originally published in Scrip

Executive Summary

Rather than pursue an initial public offering this year, personalized cancer immunotherapy developer Argos Therapeutics raised $25 million in a Series D financing round to fund its Phase III ADAPT clinical trial for AGS-003 in metastatic renal cell carcinoma (mRCC) through mid-2013 when it will have interim data to support additional venture capital investment, an IPO or a partnership.

You may also be interested in...



Argos Not Stopping Cancer Vaccine Study Despite Futility

The biotech suggests that ADAPT trial design was not ideally structured to show the longer-term benefit that might result from its autologous immunotherapy. Argos plans to discuss its plan with FDA in May, despite analyst skepticism.

Five-Plus-Five Equals A Focus On Execution At Lilly In 2023

Executives told Scrip the company is ready to move five programs into Phase III and launch five products this year, including an obesity indication for Mounjaro, but one drug has since received a CRL.

Finance Watch: Fundraising Shows Preference For Later-Stage Companies

Recent financings, including the $150m launch of Pathalys and a planned $100m IPO for Mineralys, illustrate the reality of biopharma funding in 2023 – that having near-term clinical trial milestones are key to fundraising this year. Companies with dwindling cash are conserving the funds they have left.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC017141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel